The company received FDA approval for new indications of its Sogroya growth hormone and announced a partnership to develop next-generation oral obesity and diabetes drugs. However, its stock faced significant pressure after its next-generation obesity shot, CagriSema, showed less weight loss than a key rival's drug, leading to multiple analyst downgrades. The company also initiated a patent lawsuit against Hims & Hers over compounded weight loss drugs. These events have intensified scrutiny on its pipeline ahead of key patent expirations.